Australian healthcare AI teams keep arriving at the same tension. Real patient data is regulated, scarce, and risky to handle. Synthetic data is abundant, cheap to produce, and unregulated in any direct sense. And models trained purely on synthetic records have a habit of failing quietly the moment they meet real patients. The right answer is conditional on the use case, not categorical.
The stakes are not abstract. Getting synthetic data wrong exposes a healthcare provider or health-tech vendor on two fronts at once: regulatory action under the Privacy Act 1988 and the My Health Records Act 2012, and clinical risk if a model trained on unrepresentative synthetic records is deployed against real patients. Serious or repeated privacy interferences now attract corporate penalties of up to $50 million. The upside, when synthetic data is used well, is access to training volumes that consent-bound real-data programmes cannot match.
This guide sets out where synthetic data genuinely helps, where it is dangerous, what Australian regulators expect you to document, and the validation discipline that separates a defensible programme from a liability.
When synthetic data is the right call
Synthetic data earns its place in four scenarios:
Augmenting a small real dataset where the underlying clinical distribution is well understood and the synthesiser is trained on representative source records
Stress-testing model behaviour on rare presentations that real data does not cover in useful volume
Generating safe demonstration data for staff training, sales environments, and partner integrations where no real record should ever appear
Privacy-preserving pre-training before fine-tuning on a smaller, properly consented real dataset
Notice the shared property across all four: the model is validated against real patient data before it touches a clinical surface. Synthetic data alone never deploys. Teams that hold that line get the volume benefits without inheriting the clinical exposure.
When synthetic data is dangerous
The failure modes are just as specific. Synthetic data fails as a primary training source when:
The clinical question is sensitive to subgroup behaviour the synthesiser does not capture, such as presentations that differ by age, sex, or ethnicity
The condition is rare and the synthesiser has too few real examples to model the distribution it is supposed to reproduce
The model will operate in a high-stakes diagnostic or treatment-recommending role
The synthesiser has been validated only on cohort-level statistics, never on patient-level realism
Each of these has produced real incidents in international healthcare AI deployments, from sepsis models that underperformed on minority cohorts to triage tools that missed rare presentations entirely. Australian teams working under the TGA's software-as-a-medical-device guidance and AHPRA's position on machine learning in clinical practice should treat them as hard stop signals, not footnotes.
What the Privacy Act actually requires
The most common misconception in Australian health-tech is that synthetic data sits outside the Privacy Act because it is not real. The OAIC's position is narrower: synthetic data derived from personal information may itself be personal information, depending on residual re-identification risk. The synthesis method matters. A generator that memorises outlier patients can reproduce them, and an outlier reproduced is a patient re-identified.
What a defensible Australian programme documents:
A privacy impact assessment of the synthesiser itself, including measured re-identification risk on outlier records
Provenance of the source data, with the explicit consent basis or applicable exemption for each cohort
Validation evidence showing the synthetic dataset's behaviour matches clinical reality at subgroup level
Downstream use restrictions that travel with the dataset, so a sales team cannot quietly repurpose what was generated for model testing
Budget for this properly. A scoped privacy impact assessment for a single synthesiser typically lands between $25,000 and $60,000 with Australian specialist firms, against remediation, notification, and legal costs that routinely pass $500,000 once a re-identification event becomes notifiable. For My Health Records data the bar is higher again: secondary use rules are strict, and synthetic derivation does not automatically take you outside them.
A validation protocol that holds up
Validation is where most synthetic-data programmes are weakest, and it is the part a regulator, an ethics committee, or a hospital procurement panel will examine first. A working protocol looks like this:
Train on synthetic, validate on a held-out real dataset the synthesiser never saw
Measure subgroup performance explicitly, not just aggregate accuracy
Check rare-case behaviour with a curated set of real examples
Re-validate quarterly against a refreshed real-data benchmark, because clinical populations drift
Write the protocol down before training starts, and make passing it a release gate rather than a retrospective. A validation standard agreed after the model is built protects nobody, least of all the patients it will eventually score.
Where Claude fits in this workflow
The documentation load is where most teams stall: privacy impact assessments, ethics submissions, validation report narratives, data-flow registers. This is exactly the work Claude compresses well. Healthcare teams we work with use Claude to draft the privacy impact assessment structure directly from synthesiser design documents, turn raw evaluation outputs into subgroup validation narratives an ethics committee can actually read, and keep the provenance register current as new cohorts are added.
The judgment stays human: which exemption applies, what residual risk is acceptable, when a validation result is good enough for a clinical setting. But the drafting, cross-referencing, and consistency checking that used to absorb a senior analyst's week comes down to hours. For a mid-sized Australian health-tech team, that is the difference between governance being a quarterly scramble and being continuous.
The pragmatic position for 2026
For most Australian healthcare AI teams, the right answer is mixed-source training: real data wherever consent and ethics approval permit, synthetic augmentation for rare cases and pre-training, and explicit patient-level validation before any clinical deployment. Synthetic data is a tool with boundaries, not a shortcut around the Privacy Act.
If your team is sizing a synthetic data programme, or working out whether the current one would survive an OAIC inquiry, book a healthcare AI consult and we will walk the boundaries with you.
